Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Impact of Anti-Inflammatory Medication Use on Breast Cancer Incidence and Survival in Elderly ER+ Breast Cancer

Principal Investigator
Name
Adrian Lee
Degrees
PhD
Institution
University of Pittsburgh Medical Center
Position Title
Professor of Pharmacology and Chemical Biology
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-725
Initial CDAS Request Approval
Jan 28, 2021
Title
Impact of Anti-Inflammatory Medication Use on Breast Cancer Incidence and Survival in Elderly ER+ Breast Cancer
Summary
As the US population continues to grow older, increasing numbers of women are presenting with breast cancers at advanced ages. It is estimated that the peak incidence of breast cancer diagnoses occurs at age 70 or older. The proportion of estrogen receptor (ER) positive tumors also increases with age: ~70% of tumors in patients aged <65 are classified as ER+, but this is >80% for patients >75. Despite ER+ tumors presenting with favorable prognostic markers, due to its frequency, ER+ disease still comprises the highest percentage of breast cancer-related deaths. Elderly patients present a clinical challenge: because these patients typically present with less aggressive tumors and are more likely to have comorbidities, overtreatment of a cancer that will not ultimately cause death can lead to a diminished quality of life; yet undertreating these patients can still lead to tumor recurrence. We hypothesize that these tumors in the elderly population are largely a product of age-related systemic inflammation in concert with changing estradiol and estrone levels. Thus, we seek to determine if long-term use of use of anti-inflammatory medications, including aspirin, NSAIDs, metformin, and statins, impacts disease incidence and survival.
Aims

The specific aims for this project include: (1) determine if use of anti-inflammatory medications (aspirin, NSAIDs, metformin, and statins) impact ER+ breast cancer incidence in the elderly (> 70 yo); (2) determine if use of anti-inflammatory medications (aspirin, NSAIDs, metformin, and statins) impact ER+ breast cancer survival in the elderly (> 70 yo).

Collaborators

Steffi Oesterreich PhD (University of Pittsburgh Medical Center)
Neil Carleton (University of Pittsburgh Medical Center)